预约演示
更新于：2025-12-04
Neomycin Sulfate
硫酸新霉素
更新于：2025-12-04
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1953-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H46N6O13 |
InChIKeyPGBHMTALBVVCIT-VCIWKGPPSA-N |
CAS号119-04-0 |
关联
35
项与 硫酸新霉素 相关的临床试验NCT06747611
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack. AA affects about 5.3 million people in the United States alone, including males and females across all ethnic groups, with a lifetime risk of 2.1%. Autoimmunity develops against the hair follicle, resulting in non-scarring hair loss that may begin as patches that can coalesce and progress to cover the entire scalp (alopecia totalis) or eventually the entire body (alopecia universalis). In AA, there is no permanent destruction of the hair follicle, and regrowth remains possible. Treatment options for AA include intralesional steroids, topical anthralin, allergic contact dermatitis with diphencyprone (DPCP), dinitrochlorobenzene (DNCB), or squaric acid dibutyl ester (SADBE), and recently janus kinase ( JAK) inhibitors. Despite the recent approval of JAKs for the treatment of extensive alopecia areata, some patients are treatment resistant, suffer relapses, or cannot take an oral immunosuppressive medication.
This study will attempt to elucidate the pre-treatment and post treatment skin and gut microbiome composition to determine whether specific bacterial species may correlate with disease or treatment response. To determine the effects of MTT on immune cell composition and activation systemically and locally in the skin, we will analyze major immune cell populations in peripheral blood samples and collect skin biopsies for histopathology and next generation sequencing analyses. Further, to determine if changes in immune cell populations affect the inflammatory response, we will profile inflammatory cytokines. To identify if changes in the gut microbiota influence the metabolic signature in AA, we will also perform untargeted metabolomics in stool gut microbiome samples and in plasma. Altogether, this comprehensive approach aims to identify the pathogenic immunological mechanisms associated with microbiome composition correlated to pre-treatment disease, post-treatment response, and any non-responders to treatment.
This study will attempt to elucidate the pre-treatment and post treatment skin and gut microbiome composition to determine whether specific bacterial species may correlate with disease or treatment response. To determine the effects of MTT on immune cell composition and activation systemically and locally in the skin, we will analyze major immune cell populations in peripheral blood samples and collect skin biopsies for histopathology and next generation sequencing analyses. Further, to determine if changes in immune cell populations affect the inflammatory response, we will profile inflammatory cytokines. To identify if changes in the gut microbiota influence the metabolic signature in AA, we will also perform untargeted metabolomics in stool gut microbiome samples and in plasma. Altogether, this comprehensive approach aims to identify the pathogenic immunological mechanisms associated with microbiome composition correlated to pre-treatment disease, post-treatment response, and any non-responders to treatment.
开始日期2025-08-21 |
申办/合作机构 |
NCT06148025
A Human Experimental Medicine Study to Assess Whether the Gut Microbiota Regulates Specific and Non-specific Immune Responses to Vaccination
The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination.
The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?
The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?
开始日期2023-11-23 |
CTRI/2023/05/053005
A randomized controlled trial to evaluate the efficacy of 2% Mupirocin vs 0.5% Neomycin vs placebo intranasal ointment on prevention of surgical site infections among adult patients undergoing cardiac surgery in AIIMS, New Delhi
开始日期2023-07-01 |
申办/合作机构- |
100 项与 硫酸新霉素 相关的临床结果
登录后查看更多信息
100 项与 硫酸新霉素 相关的转化医学
登录后查看更多信息
100 项与 硫酸新霉素 相关的专利（医药）
登录后查看更多信息
7,786
项与 硫酸新霉素 相关的文献（医药）2026-02-01·BIOMATERIALS
Reversible shear stress-mediated mechanoregulation of endothelial cell function in thixotropic hydrogels via L-type Ca2+ channel and focal adhesion molecules for accelerated vascularization
Article
作者: Qu, Shuxin ; Xie, Chaoming ; Jing, Tao ; Li, Sumei ; Gou, Xue ; Peng, Haodong ; Wang, Ran ; Li, Zhongtao ; Cui, Rongwei ; Lin, Feng ; Weng, Jie
Developing functional vascular networks in engineered tissues is crucial for regenerative medicine. Recently, thixotropic hydrogel has emerged as a promising approach due to their 3D-printability and force-responsive dynamics. However, their gel-sol transitions under physiological loading and subsequent mechanoregulation mechanism on vascularization remains inadequately explored. Here, the reversible shear stress induced in thixotropic hydrogels under bionic cyclic stretching (5 % strain, and 0.5, 1 or 1.5 Hz) has been demonstrated to significantly accelerate endothelial cell adhesion, migration, and angiogenesis. These dynamic mechanical responses are precisely quantified and monitored through computational simulations and specially designed experimental apparatus. Mechanistic investigations reveals that the mechanically regulated cell behavior is mediated by cell adhesion molecules and calcium signaling pathways, which can be inhibited using Talin bloker (e.g., neomycin) and L-type voltage-gated calcium channel antagonists (e.g., verapamil), respectively. Furthermore, subcutaneous implantation of thixotropic hydrogels in rats results in denser and more rapid vascularization compared to non-thixotropic hydrogels. The reversible shear stress-regulated vascularization strategy is anticipated to offer a novel and efficient approach for constructing functional blood vessels in regenerative medicine.
2026-01-01·BRAIN BEHAVIOR AND IMMUNITY
Systematic screening identifies medication and disease factors associated with schizophrenia risk
Article
作者: Israel, Ariel ; Merzon, Eugene ; Israel, Sarah ; Magen, Eli ; Stokar, Joshua ; Ashkenazi, Shai ; Vinker, Shlomo ; Weizman, Abraham
Schizophrenia (SCZ) is a severe psychiatric disorder with a complex and poorly understood etiology. Previous studies have linked Toxoplasma gondii infection to SCZ, though its clinical relevance remains uncertain. To identify factors associated with SCZ risk, we analyzed electronic health records from a national Israeli health provider, retrospectively comparing 3,273 individuals with SCZ to 32,730 matched controls. We systematically screened all medication purchases and medical diagnoses recorded from 10 years to 30 days before SCZ onset. Significant associations, adjusted for residual confounding, were further evaluated in the TriNetX network, where large propensity score-matched cohorts were compared for incident SCZ following medication exposure. Among all medication classes screened, strong protective associations were detected for specific antimicrobials, notably atovaquone/proguanil, clindamycin, and ophthalmic fluoroquinolones. Nonsteroidal anti-inflammatory drugs, particularly COX-2 inhibitors, were also linked to reduced SCZ risk, whereas neomycin, tramadol, and desmopressin were associated with increased risk. Key associations were confirmed within TriNetX with high statistical significance. These observational findings, reproduced across two national cohorts, are hypothesis-generating and may reflect multiple, non-exclusive mechanisms, including antimicrobial, anti-inflammatory, and microbiome-related pathways, with T. gondii elimination through antiprotozoal activity representing one compelling explanatory hypothesis that warrants further investigation.
2025-12-31·DRUG DELIVERY
Peptides rapidly transport antibiotic across the intact tympanic membrane to treat a middle ear infection
Article
作者: Kurabi, Arwa ; Ryan, Allen F. ; Sereno, Emily
The tympanic membrane (TM) forms an impenetrable barrier to medical therapies for middle ear (ME) diseases like otitis media. By screening a phage-displayed peptide library, we have previously discovered rare peptides that mediate the active transport of cargo across the intact membrane of animals and humans. Since the M13 filamentous bacteriophage on which the peptides are expressed are large (nearly 1 µm in length), this offers the possibility of noninvasively delivering drugs, large drug packages, or gene therapy to the ME. To evaluate this possibility, EDC chemistry was employed to covalently attach amoxicillin, or neomycin molecules to phage bearing a trans-TM peptide, as a model for large drug packages. Eight hours after application of antibiotic-phage to the TM of infected rats, ME bacterial titers were substantially reduced compared to untreated animals. As a control, antibiotic was linked to wild-type phage, not bearing any peptide, and application to the TM did not affect ME bacteria. The results support the ability of rare peptides to actively deliver pharmacologically relevant amounts of drugs through the intact TM and into the ME. Moreover, since bacteriophage engineered to express peptides are viral vectors, the trans-TM peptides could also transport other viral vectors into the ME.
32
项与 硫酸新霉素 相关的新闻（医药）2025-12-03
Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review
抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述
Konstantinos Alexakis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771,
2
To be or not to be: the non-antimicrobial properties of common antimicrobials
生存还是毁灭：常见抗菌药物的非抗菌特性
Shivakumar Narayanan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783,
SYSTEMATIC REVIEWS（系统综述）
3
Antibiotic-induced Bartter-like syndrome: a systematic review
抗生素诱发的巴特综合征样表现：系统综述
Megha Priyadarshi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791,
4
Liposomal amphotericin B prophylaxis in paediatrics: a systematic review
两性霉素B脂质体预防性用药在儿科中的应用：系统综述
Emma V Thorley and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802,
ORIGINAL RESEARCH（论著）
5
Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study
婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究
Sarah F Hak and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812,
6
Plasmodium falciparum isolates: ex vivo drug response
恶性疟原虫分离株：体外药物反应
Edem Adika and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822,
7
Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia
低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827,
8
Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England
探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法
Ming Xuan Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836,
9
Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study
新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究
Yulia Butscheid and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848,
10
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析
Alessandro Cozzi-Lepri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859,
11
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model
基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型
Diego Vera-Yunca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868,
12
Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine
线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关
J R Macdonald and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877,
13
Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium
米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性
Kay Htaik and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884,
14
Early use of the novel antifungal rezafungin: a case series and literature review
新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述
H C Davidson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892,
15
Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach
基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量
Gisela Myrian de Lima Leite Dalla Rosa and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901,
16
Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade
过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关
Aliya El Nagar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906,
17
An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections
一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响
Mariagrazia Ciardo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914,
18
Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients
利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估
Xiaoping Shi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925,
19
Rapid susceptibility testing on urine for antimicrobial stewardship in general practice
全科实践中的尿液快速药敏试验助力抗菌药物管理
Patrick D J Sturm and Tanja Schülin
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932,
20
Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains
利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941,
21
In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains
新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性
Marie L G Attwood and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946,
22
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions
中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性
Nadiia Mosiichuk and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950,
23
Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China
中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征
Zeqiang Zhan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963,
24
High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study
根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集
Zhengyu Luo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971,
25
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus
抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响
Aliona S Rosca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979,
26
Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study
肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究
Lijuan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987,
27
Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875
多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征
Jonathan Koong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992,
28
Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum
改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较
Doris Hillemann and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996,
29
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations
由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转
Paschalis Paranos and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006,
30
Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France
瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构
Sofie M Edslev and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015,
31
Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections
抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估
Nischal Ranganath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024,
32
Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control
肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法
Ana Beatriz Gonçalves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031,
33
Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori
抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性
Paweł Krzyżek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043,
34
A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro
生殖支原体体外诱导产生的新型阿奇霉素耐药突变
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050,
RESEARCH LETTERS（研究信函）
35
Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations
婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度
Jeffrey Harrington and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053,
36
Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis
两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法
Natacha Mrozek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056,
37
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?
头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？
Alexandra Morin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058,
LETTER TO THE EDITOR（致编辑的信）
38
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint
单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点
Miguel Villamarín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 8
抗菌化疗杂志 80卷 8期
https://academic.oup.com/jac/issue
Review(综述)
1
World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’
世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇”
Vazhayil Hari Krishnaprasad and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069
Original Research(论著)
2
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023)
氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结
Helio S Sader and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079
3
High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid
利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究
Hitoshi Kawasuji and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091
4
Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium
缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析
Yukitaka Hayashi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099
5
Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial
为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验
Nusrat Shafiq and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108
6
An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy
用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型
Cole McGrath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116
7
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa
黏液型铜绿假单胞菌纸片扩散法的优化与改进
Aixin Wang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125
8
HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022
乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查
Christine Watera and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134
9
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women
与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究
Sharana Mahomed and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144
10
Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study
接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究
Javier García-Abellán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157
11
Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model
慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究
Midas B Mulder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168
12
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据
Roberta Gagliardini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178
13
Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial
病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验
Hsin-Yun Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186
14
Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia
青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究
Pernilla Kihlberg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193
15
Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202
16
Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway
齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌
Yun-Dan Zheng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213
17
Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study
阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究
Tom C Zwart and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225
18
48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析
Elisa de Lazzari and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233
19
The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time
多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响
Trenton Honda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240
20
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales
一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估
Christian Moguet and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246
21
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes
粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究
Matteo Rinaldi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256
22
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus
靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染
Robin H G A van den Biggelaar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268
23
Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm
基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279
24
Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy
意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件
Andrea Brenciani and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284
25
Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022
2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征
Corentin Poignon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294
26
Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections
具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁
Ye Jin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304
27
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性
Simon E Koele and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313
28
Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study
头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究
Dimitrios Basoulis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322
Research Letters(研究信件)
29
Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring
达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告
Carlo Pallotto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324
30
A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs
韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174）
Hyeonwoo Cho and Kun Taek Park
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326
31
Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report
时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告
Layla Pagnucco and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330
32
Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48
土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征
Astrid Rasmussen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331
Letters to the Editor(致编辑的信)
33
Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital
述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究
Jianjun Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332
34
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response
产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复
Gulhadiye Avcu
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333
Corrections(更正)
35
Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD)
更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334
36
Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs
更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335
37
Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics
更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2
抗菌化疗杂志 80卷 增刊2期
https://academic.oup.com/jac/issue
SUPPLEMENT (补充)
CANWARD 2007-23
加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告
Foreword(前言)
1
The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection
加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集
James C Hurley and Jean-Yves Madec
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1
Supplement Papers(补充论文)
2
Seventeen years of the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究17年（2007-2023年）
George G Zhanel and Heather J Adam
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4
3
Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14
4
Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26
5
Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023）
Anissa Brahami and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34
6
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23）
Heather J Adam and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44
7
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23
加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023
Philippe Lagacé-Wiens and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53
8
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23）
Laura F Mataseje and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61
9
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23)
加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23）
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71
10
Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23)
加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果
Andrew Walkty and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82
Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Classifying patients with invasive fungal disease: towards a unified case definition?
侵袭性真菌病患者分类：能否达成统一的病例定义？
Mehmet Ergün and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343,
SYSTEMATIC REVIEW（系统综述）
2
Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis
早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析
ZhaoYi Tan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360,
ORIGINAL RESEARCH（论著）
3
Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium
屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定
Maria Laura Ferrando and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368,
4
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era
四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响
Rebecka Papaioannu Borjesson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374,
5
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks
随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响
Parul Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383,
6
Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea
基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据
So Yun Lim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390,
7
A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme
摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准
Aymeric Jacquemin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398,
8
Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya
2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征
Diana Imoli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407,
9
Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection
经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响
Tao-Hung Ou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416,
10
Safety of topical tobramycin powder during operative treatment of fractures
骨折手术中使用局部妥布霉素粉末的安全性
Gregory M Schrank and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420,
11
Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS
复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析
Rinko Lau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427,
12
Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England
从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌
Satheesh Nair and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432,
13
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics
克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用
Siddharth Singh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441,
14
Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446,
15
Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo
DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用
Xuemin Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458,
16
A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology
采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究
Joseph Meletiadis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465,
17
Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study
万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析
M Del Monte and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473,
18
Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient
异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现
Martyna Pociupany and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483,
19
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486,
20
Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database
使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析
Yongseop Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495,
21
Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024
2024年中国河南省HIV-1感染者传播耐药情况
Jinjin Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502,
22
Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance
A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性
Makiko Noda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512,
23
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization
头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征
Clara Moretó-Castellsaguéand others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523,
24
Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates
达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529,
25
Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation
伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响
Wenjie Cui and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540,
26
Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up
加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响
Freshwork Ayalew Abegaz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549,
RESEARCH LETTERS（研究快信）
27
TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient
治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染
Giovanni Mulé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552,
28
Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage
城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759
Xinyuan Qiu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555,
29
Characterization of multiresistance gene optrA in Bacillus subtillis from China
中国枯草芽孢杆菌中多重耐药基因optrA的特征分析
Yongliang Che and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557,
30
Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China
从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征
Fuqiang Ye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560,
LETTERS TO THE EDITOR（致编辑的信）
31
Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events
关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论
Mi Zhou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562,
32
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study
关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论
Satoru Mitsuboshi
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563,
33
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response
住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead
长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586,
2
Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估
James C Hurley
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596,
SYSTEMATIC REVIEWS（系统综述）
3
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
研究肺结核治疗的肺内药代动力学：方法学的系统综述
Isabella van der Feltz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608,
4
Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis
全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析
Christopher Larkin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621,
ORIGINAL RESEARCH（研究论著）
5
Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？
Paula Bierge and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629,
6
Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023
2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测
Nguyen Van Thanh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634,
7
Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia
哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性
Savan Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643,
8
Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia
连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度
Claire Roger and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653,
9
Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial
头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验
Tamara Klementová and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658,
10
Trends in antifungal use among hospitalized patients in the USA, 2018–23
2018-2023年美国住院患者抗真菌药物使用趋势
Dallas J Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664,
11
Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study
BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究
Louis Oudiane and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675,
12
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium
甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性
Sofie Skovmand and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681,
13
A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model
基于群体药代动力学模型的左氧氟沙星剂量方案先验优化
Emmanuel Enard and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692,
14
Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis
危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析
Tingting Wu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704,
15
Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria
开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标
Irene Zaghi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713,
16
In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model
头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718,
17
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验
Jinhee Jo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726,
18
Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application
抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示
Nathan Engel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731,
19
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study
意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741,
20
Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study
使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究
Hiroki Katsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751,
21
Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial
BALANCE临床试验中血流感染患者的临床病程
Sean W X Ong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758,
22
Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study
神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究
Qian Zeng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772,
23
Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781,
24
Population pharmacokinetics of bictegravir in real-world people with HIV
现实中HIV感染者比克替拉韦的群体药代动力学
Pierre Ekobena and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789,
25
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index
活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响
Teres Samuelsson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798,
26
Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806,
27
Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model
在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移
Solene Labaye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813,
28
Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms
针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用
Justin Halim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824,
29
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France
2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验
L Sagaon-Teyssier and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833,
30
Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin
对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征
Emilia Cercenado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843,
31
Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA
美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构
Chih-Hao Hsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853,
32
Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii
鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征
Jingchen Hao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861,
33
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones
各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征
Jing Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872,
RESEARCH LETTERS（研究快报）
34
Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?
奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？
Giulia Turicchi and Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874,
35
The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii
catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876,
36
Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas
携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播
Roberto Sierra and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879,
37
Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae
替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性
Julie Brousseau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881,
LETTERS TO THE EDITOR（致编辑的信）
38
Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus
述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性
Karl Oldberg and Magnus Rasmussen
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883,
39
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究
Giancarlo Ceccarelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885,
40
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response
住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886,
Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷 增刊4期
https://academic.oup.com/jac/issue/80/Supplement_4
SUPPLEMENT（补充）
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
FOREWORD（前言）
1
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
James C Hurley and Alan P Johnson
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1,
SUPPLEMENT PAPERS（补充论文）
2
Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions
英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向
Alasdair P MacGowan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6,
3
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations
英国抗菌化疗学会耐药性监测项目：方法与局限性
Michael Allen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21,
4
Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35,
5
Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48,
6
Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019
英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59,
7
Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019
英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71,
8
Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019)
英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年）
Carolyne Horner and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86,
9
Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future
英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来
Benjamin J Parcell and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期
https://academic.oup.com/jac/issue
VIEWPOINTS（观点）
1
Modification of antimicrobial susceptibility testing methods
抗菌药物敏感性检测方法的修改
Ian Morrissey and Jean B Patel
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888,
2
Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA
观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验
Ashley M Wilde and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891,
REVIEWS（综述）
3
Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules
噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式
Cleo Anastassopoulou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901,
4
Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications
融合质粒的分子驱动因素：机制见解与进化意义
Ziyi Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911,
ORIGINAL RESEARCH（研究论著）
5
Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry
泰国养猪业中出现与牲畜相关的MRSA克隆复合体398
Pawarut Narongpun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917,
6
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series
长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告
Tomaso Beringheli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922,
7
Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections
细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点
Yao Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933,
8
The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus
acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用
Jiahui Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944,
9
Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究
Thibaut Gelé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953,
10
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare
胞内分枝杆菌中与氯法齐明耐药相关的新型突变
Xiuzhi Jiang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957,
11
Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria
基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性
Mariana Romero-Gonzalez and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969,
12
In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin
体外进化揭示生殖支原体对莫西沙星的耐药机制
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977,
13
The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening
毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性
Weifeng Xu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988,
14
Molecular insights into carbapenemase-producing Enterobacterales from Senegal
塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征
Ousmane Sow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000,
15
Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients
老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型
Xianglong Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010,
16
In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China
在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性
Rongqi Lu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020,
17
Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain
从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒
Yao Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025,
18
Multidrug resistance and recurrence in urinary bacteraemia among cancer patients
癌症患者中尿路菌血症的多药耐药性和复发情况
Ignacio Grafia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033,
19
Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection
在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药
Ping Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042,
20
Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals
伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险
Jirachaya Toyting-Hiraishi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056,
21
Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales
液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估
Anna Witkowska and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064,
22
Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus
毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性
Stephanie Toepfer and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078,
23
Ivermectin dosing for children under 2 years
2岁以下儿童的伊维菌素剂量
Wenyu Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081,
24
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据
Alessandra Vergori and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091,
25
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic
城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素
Geoffroy Liegeon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100,
26
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究
D Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106,
27
Sequential antibiotic exposure restores antibiotic susceptibility
序贯抗生素暴露恢复抗生素敏感性
Farhan R Chowdhury and Brandon L Findlay
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117,
28
Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study
在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现
Ling-Ya Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122,
29
Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt
埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性
Mohamed Eladawy and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132,
30
How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?
在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？
Marie Gilbert and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138,
31
In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species
奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149,
32
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis
在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用
Christopher A Darlow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159,
33
High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon
喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高
Armando B D Djiyou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164,
RESEARCH LETTERS（研究快讯）
34
SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants
新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性
Bram Spruijtenburg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166,
35
Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?
替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？
Andrea Poloni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168,
36
Does the use of topical azoles have an impact on antifungal resistance?
局部使用唑类药物对抗真菌耐药性有影响吗？
Jean-Yves Maillard
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186,
37
Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy
接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况
Samir Benkouiten and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188,
CORRECTION（更正）
38
Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 12抗菌化疗杂志 80卷 12期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying ‘breakpoints in brackets’
利福平单药治疗金黄色葡萄球菌感染：关于不应用“括号内折点”的考量
Sara E Boyd and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3191–3193,
REVIEWS（综述）
2
The Achilles’ heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing
特洛伊木马的致命弱点？头孢地尔药敏试验的系统评价
Deny Tsakri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3194–3207,
3
Antifungal treatment strategies and their impact on resistance development in clinical settings
抗真菌治疗策略及其对临床环境中耐药性发展的影响
Norman Van Rhijn and P Lewis White
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3208–3226,
ORIGINAL RESEARCH（论著）
4
Decrease in colistin resistance among young bovine and pig productions in France: relationship with colistin usage and stewardship measures
法国年轻牛和猪生产中多粘菌素耐药性的下降：与多粘菌素使用及管理措施的关系
Claire Chauvin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3227–3235,
5
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments
接受联合抗病毒治疗的活动性血液系统疾病患者感染SARS-CoV-2后恢复抗癌治疗的时间
E Matteini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3236–3241,
6
From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV
从三联疗法到单一疗法：在多重耐药HIV感染且治疗经验丰富的人群中简化使用比克替拉韦/恩曲他滨/丙酚替诺福韦
José L Casado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3242–3247,
7
Effects of commonly used antibiotics on children’s developing gut microbiomes and resistomes in peri-urban Lima, Peru
秘鲁利马市郊常用抗生素对儿童发育中的肠道微生物组和耐药组的影响
Neha Sehgal and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3248–3256,
8
Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study
衰弱指数实验室（FI-Lab）作为预测院内多重耐药肺炎克雷伯菌血流感染不良预后的指标：一项单中心回顾性队列研究
Carmen Pellegrino and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3257–3264,
9
Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes
体外衍生的产OXA-48样酶肺炎克雷伯菌突变体对头孢他啶/阿维巴坦的耐药机制
T Blanco-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3265–3272,
10
Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales
肠杆菌目中氨曲南/阿维巴坦药敏试验的纸片扩散法和肉汤微量稀释法的比较评价
Ioannis Baltas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3273–3277,
11
Efficacy of topical hydrophilic gel of paromomycin combined with systemic or locally administered leishmanicidal drugs for treatment of experimental leishmaniasis caused by Leishmania (Viannia) braziliensis
硫酸巴龙霉素亲水性凝胶局部用药联合全身或局部使用杀利什曼原虫药物治疗巴西利什曼原虫（Viannia亚属）引起的实验性利什曼病的疗效
Líndicy Leidicy Alves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3278–3287,
12
Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies
血液系统恶性肿瘤患儿中头孢噻利的群体药代动力学及剂量优化
Jing-Rui Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3288–3296,
13
Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol
治疗产超广谱β-内酰胺酶（ESBL）和/或AmpC酶且不产碳青霉烯酶的肠杆菌目细菌的挑战：新型β-内酰胺/β-内酰胺酶抑制剂组合和头孢地尔的体外评价
Inès Rezzoug and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3297–3305,
14
Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study
使用多西环素进行暴露后预防（DoxyPEP）以在现实环境中预防性传播感染：PRIDOX研究
R Palacios and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3306–3310,
15
Risk–benefit balance of blood cultures among patients with stage IV cancer in unplanned admission: a nationwide propensity score–weighted study in Japan
日本全国范围内倾向评分加权研究：IV期癌症患者非计划入院时血培养的风险-获益平衡
Yuki Hashimoto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3311–3319,
16
A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma
对美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的药物进行药物再利用筛选，发现两种对真性着色真菌病有活性的NF-κB抑制剂
Jingyi Ma and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3320–3328,
17
Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study
替莫西林与其他静脉注射β-内酰胺类药物治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Jeanne Iachkine and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3329–3334,
18
Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections
感染科医生对碳青霉烯耐药肠杆菌目感染的治疗偏好
Samuel E Cincotta and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3335–3339,
19
The aphA1 kanamycin and neomycin resistance gene originated in Klebsiella michiganensis
aphA1卡那霉素和新霉素耐药基因起源于密歇根克雷伯菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3340–3344,
20
Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance
头孢他啶-阿维巴坦耐药且不产碳青霉烯酶的碳青霉烯耐药肠杆菌目的全球易感性特征和潜在耐药机制：2020-2023年来自抗菌药物测试领导与监测的数据
Chih-Cheng Lai and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3345–3351,
21
Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa
头孢他啶-阿维巴坦联合氨曲南与固定组合氨曲南/阿维巴坦对多重耐药铜绿假单胞菌的体外活性比较
Sophie E Müller and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3352–3356,
22
Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes
粪肠球菌中双重β-内酰胺协同作用及其与青霉素-头孢曲松感染性心内膜炎治疗结果的关系
April Gregson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3357–3366,
23
The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing
走向短半衰期的漫长之路：发现肾增强清除及其对抗菌药物剂量调整的影响
Jeffrey Lipman and Russell E Lewis
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3367–3374,
24
Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections
氨曲南-阿莫西林/克拉维酸联合治疗产blaNDM肠杆菌目感染
Efrat Orenbuch-Harroch and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3375–3380,
25
Evaluation of sodium zirconium cyclosilicate usage for hyperkalaemia secondary to sulfamethoxazole/trimethoprim therapy
评估锆酸钠环硅酸盐用于磺胺甲恶唑/甲氧苄啶治疗继发的高钾血症
Dixie Pyles and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3381–3385,
26
Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis
每周三次血液透析后使用头孢他啶可在类鼻疽患者中达到足够的透析前浓度并实现临床治愈
Simon Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3386–3390,
27
In vitro and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent
体外和临床数据表明，新型吸入抗真菌药物奥培康唑的药物-药物相互作用风险可忽略不计
Lindsey M R Cass and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3391–3400,
28
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial
在ALLG AMLM16试验中，FLT3-ITD阳性急性髓系白血病患者在初始诱导和巩固治疗期间接受索拉非尼治疗时的抗真菌预防
Chin Fen Neoh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3401–3406,
29
The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections
基于替加环素的联合用药对多重耐药鲍曼不动杆菌引起的血流感染的协同活性
Huan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3407–3418,
30
Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage?
儿科患者中哌拉西林的剂量调整与肾增强清除：现行指南是否足以达到治疗浓度覆盖？
Anne Ravix and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3419–3430,
31
Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model
在中性粒细胞减少的小鼠大腿感染模型中评估人模拟氨曲南-阿维巴坦对嗜麦芽窄食单胞菌的疗效
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3431–3437,
32
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)
西班牙HIV感染者长期使用卡博特韦和利匹韦林的有效性和持久性的前瞻性评估（RELATIVITY研究）
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3438–3451,
33
Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
奥洛罗芬和伏立康唑对烟曲霉的体外拮抗作用
Illan Laloum and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3452–3461,
RESEARCH LETTERS（研究快讯）
34
Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury
静脉注射万古霉素联用导致大剂量甲氨蝶呤清除延迟和急性肾损伤
Thao Dao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3462–3464,
35
Overestimation of piperacillin/tazobactam resistance in Escherichia coli by disc diffusion and gradient strip methods
纸片扩散法和梯度条法高估大肠埃希菌对哌拉西林/他唑巴坦的耐药性
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3464–3467,
36
Mind the gap: missed re-initiation and monitoring in statin–antimicrobial co-prescriptions
注意差距：他汀类药物与抗菌药物联合处方中的漏重新起始和监测
Melwin Kyle Solis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3467–3468,
37
Pharmacokinetics of aztreonam/avibactam in a critically ill patient with a class B metallo-β-lactamase producing Enterobacteriaceae and receiving continuous renal replacement therapy
一名接受连续肾脏替代治疗且感染产B类金属β-内酰胺酶肠杆菌科细菌的重症患者中氨曲南/阿维巴坦的药代动力学
Daniel Fresán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3469–3471,
CORRECTION（更正）
38
Correction to: Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
更正：系统评价与《抗菌药物化疗杂志》：过去、现在和未来。一项系统再评价
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3472–3473,
2025-12-02
·MEDP
（接前文）
2.夫西地酸
夫西地酸是一种类固醇类抗生素，具有独特的夫西丹类固醇核，但缺乏皮质类固醇活性。它是从真菌绯红梭链孢(Fusidium coccineum)的发酵液中分离出来的。
作用机制：夫西地酸是一种细菌蛋白质合成抑制剂。其机制不同于其他核糖体抗生素。它特异性靶向并抑制伸长因子G（EF-G）。EF-G是一种关键蛋白质，可促进肽基tRNA从A位点易位到核糖体上的P位点，这是多肽链延长的关键步骤。夫西地酸与EF-G-核糖体-GDP复合物结合，将EF-G“锁定”在核糖体上并阻止其释放，从而阻碍蛋白质合成并最终抑制细菌生长。
抗菌谱：夫西地酸是一种窄谱药物，其活性几乎只针对革兰氏阳性菌。
👉革兰氏阳性菌：它对金黄色葡萄球菌（包括MRSA菌株）、大多数凝固酶阳性葡萄球菌、棒状杆菌属和大多数梭状芽孢杆菌具有高度活性。
👉革兰氏阴性菌：它对绝大多数革兰氏阴性菌（如肠球菌和假单胞菌）没有已知的有用活性。
👉链球菌：与莫匹罗星的重要区别在于其对链球菌的活性。体外数据显示，对化脓性链球菌的最小抑菌浓度（MIC）相对较高，表明其具有“有限活性”。这使其成为高效的抗葡萄球菌药物，但作为抗链球菌药物则效果存疑。
药代动力学：夫西地酸有外用、口服和静脉注射三种剂型。外用时，该药物能被皮肤充分吸收。其高蛋白结合率（超过95%）可能导致体外敏感性试验结果复杂化，在含血或血清的检测介质中，这种特性会影响药物的生物利用度和活性。夫西地酸尚未被美国FDA批准在美使用。
3．三抗生素组合（TAO，复方多黏菌素B软膏）
三抗生素软膏（TAO），原研产品以Neosporin品牌而闻名，是一种非处方（OTC）制剂，自1952年起一直在广泛使用。我国自2006年起也上市这个同类产品，叫“复方多黏菌素B软膏”。这个产品与前两种外用抗生素制剂不同，其是一种经典的复方制剂，由三种不同抗生素组合而成：杆菌肽、新霉素和多黏菌素B。
本制剂的研发理念是创建一种广谱、长效的预防性治疗药物，用于预防和治疗轻微割伤、擦伤和烧伤部位的细菌感染。通过将三种具有不同作用机制且抗菌谱互补的抗生素组合，使得药物制剂能覆盖污染伤口的最常见革兰氏阳性菌和革兰氏阴性菌，从而最大限度降低感染风险并促进自然愈合。
（1）杆菌肽
👉机制：杆菌肽是一种多肽类抗生素。它通过破坏革兰氏阳性菌的细胞壁合成来发挥作用。具体而言，它干扰脂质载体分子（C55-异戊烯基焦磷酸）的去磷酸化过程——该分子负责将肽聚糖（细胞壁主要成分）的构建块从细胞质运输至细胞膜外部。此阻断作用导致细胞壁构建停止。
👉作用范围：其活性主要针对革兰氏阳性菌，包括皮肤主要致病菌金黄色葡萄球菌和化脓性链球菌。
（2）新霉素
👉机制：新霉素是一种氨基糖苷类抗生素。它通过不可逆地结合于30S核糖体亚基的16S rRNA来抑制细菌蛋白质合成。这种结合干扰了核糖体对mRNA-tRNA复合物的“校对”能力，导致产生非功能性或截短蛋白质，最终引发细菌细胞死亡。
👉抗菌谱：新霉素主要针对革兰氏阴性菌，如大肠杆菌和克雷伯氏菌属。
（3）多黏菌素B
👉机制：多黏菌素B是另一种多肽类抗生素，但其作用机制与杆菌肽完全不同。它作为阳离子表面活性剂发挥作用，对革兰氏阴性菌外膜中带负电荷的脂多糖（LPS）分子具有高亲和力。这种结合破坏了细菌外膜的完整性和通透性，导致必需的细胞内物质外泄并引发细胞死亡。
👉抗菌谱：其活性仅限于革兰氏阴性菌。它是少数几种对铜绿假单胞菌具有可靠体外活性的局部抗生素之一。
以上三种抗生素合在一起，组成了一个完全覆盖革兰氏阳性菌和阴性菌的全广谱外用抗生素制剂。
表2：主要外用抗生素的作用机制和抗菌谱
抗生素
药理学类
作用机制
主要抗菌谱
莫匹罗星
RNA合成酶抑制剂
抑制异亮酰-tRNA合成酶，阻断蛋白质和RNA合成。
广谱但只针对革兰氏阳性：对金黄色葡萄球菌（MSSA和MRSA）和化脓性链球菌高活性。
夫西地酸
类固醇抗生素
通过结合核糖体上的伸长因子G来抑制蛋白质合成。
窄谱且只针对革兰氏阳性：对金黄色葡萄球菌（MSSA和MRSA）和棒状杆菌属活性强；对化脓链球菌活性有限。
杆菌肽
多肽类抗生素
通过干扰肽聚糖的脂质载体来抑制细胞壁合成。
革兰氏阳性：针对金黄色葡萄球菌和化脓性链球菌。
新霉素
氨基糖苷类抗生素
通过与30S核糖体亚基结合来抑制蛋白质合成。
革兰氏阴性：针对大肠杆菌、克雷伯菌属和其他肠杆菌科。
多黏菌素B
多肽类抗生素
作为阳离子去垢剂，破坏革兰氏阴性菌的外细胞膜。
革兰氏阴性：针对铜绿假单胞菌、大肠杆菌、克雷伯菌属。
三．最常用三种外用制剂的抗生素敏感性和耐药性分析
外用抗生素制剂同样受微生物药物耐药性（AMR）这一深刻且快速演变的挑战。随着这些外用制剂（无论处方药还是非处方药）的广泛使用，会形成巨大的选择压力，导致耐药菌株出现并威胁其临床应用价值。以下综合了当前临床疗效数据与近期（2024-2025年）耐药性监测数据，介绍外用抗菌药物管理面临的严峻危机。
1．莫匹罗星的疗效和耐药性
（1）核心功效（“金标准”）
莫匹罗星被广泛认为是许多浅表皮肤感染的一线处方药物，这主要是因为它对两种最常见的病原体具有很高的疗效。
👉针对金黄色葡萄球菌（MSSA和MRSA）：莫匹罗星是局部治疗金黄色葡萄球菌引起的皮肤软组织感染（SSTI）的基石。该药获得FDA的批准，对治疗脓疱疮及继发性皮肤感染具有显著疗效。然而其最关键的应用在于院内感染的控制：莫匹罗星的鼻腔给药是清除鼻腔金黄色葡萄球菌（包括MSSA和MRSA）的金标准。该去定植方案经证实可降低医疗环境中金黄色葡萄球菌传播风险，并预防患者院内术后切口的感染。2024年一项大规模集群随机试验显示，在重症监护室患者中，莫匹罗星比消毒剂碘伏更显著有效地减少金黄色葡萄球菌及MRSA的临床培养阳性率。早期针对特定场景的研究（如儿童烧伤创面MRSA感染）证实，莫匹罗星能有效清除所有治疗创面中的病原体。
👉针对化脓性链球菌：莫匹罗星对治疗由化脓性链球菌引发的原发性及继发性皮肤感染同样具有高效且安全的特性。这点很重要，因为脓疱疮常由化脓性链球菌或金黄色葡萄球菌与化脓性链球菌的混合感染所致。该药物对这两种主要病原体均具高效抑制作用，使其成为治疗脓疱疮的理想经验性选择，此观点亦获美国感染病学会（IDSA）推荐。
（2）莫匹罗星耐药性危机
莫匹罗星的成功与实用性实际上也反而成了其最大隐患。其广泛应用——尤其在群体去定植方案中的使用——导致莫匹罗星耐药性急剧且危险地增加，威胁着该药物的持续疗效。
莫匹罗星独特的抗药性机制使其成为控制耐甲氧西林金黄色葡萄球菌（MRSA）的首选药物。但这种应用方式会形成了强大的选择压力，促使能够克服其药效的菌株得以存活和扩散。如今，这种耐药性正在破坏原本一直使用的去定植策略。目前已确认两种不同的莫匹罗星耐药形式：
A．低水平莫匹罗星耐药性（LL-MR）：这通常是由细菌原生染色体中异亮氨酰-tRNA合成酶基因的点突变引起的。该突变会轻微改变酶的结构，降低莫匹罗星的结合亲和力。由此导致的最小抑菌浓度升高（例如由4上升到<100 mg/mL），这种耐药性在外用软膏能达到极高浓度时，有时还可克服。
B．高水平莫匹罗星耐药性（HL-MR）：这是一种更为严重的临床威胁。其成因并非简单的突变，而是细菌通过可移动质粒获得了新的mupA基因。该基因编码的异亮氨酰-tRNA合成酶具有全新结构，且具有极强的耐药性。这种突变赋予了极高水平的耐药性（最小抑菌浓度MIC 86上升至> 500 mg/mL），已无法通过局部用药来抑制，且与临床治疗失败及去定植方案失效密切相关。由于mupA耐药基因在质粒上，它能与其他耐药基因一起在细菌间轻易转移。
这种耐药性已不再是零星发现。一项2024年的监测研究（追踪2000-2004年数据）指出，在研究的医院中，53%的医院发现了MRSA中的HL-MR，其在MRSA菌株中的发生率从0%到26%不等（中位数为3%）。
更令人忧虑的是，关键的2024/2025年数据显示该流行率可能被严重低估。2025年1月发表的一项研究（分析美国大型医疗系统2023-2024年数据）调查了MRSA分离株中mupA基因的流行率，结果令人震惊：
👉在所有MRSA分离株中，高水平耐药基因mupA的总体流行率为22.0%。
👉作者指出该比例“远高于既往报道”，尤其在特定MRSA菌株中更为显著。
22%的“惊人高耐药率”意味着：在此医疗体系中，常规MRSA去定植方案（鼻腔内用莫匹罗星）预计将对五分之一以上的MRSA定植患者失效。
以上的研究数据还是在对抗生素有严格限制使用监管控制，并且莫匹罗星软膏是作为处方药管理的美国的临床研究结果。试推测想象下在我国作为非处方药管理的环境下，这种耐药性的真实发展状况目前可能实际已经达到了什么样的境地了。
2.夫西地酸的疗效和耐药性
（1）核心功效（专门用于金黄色葡萄球菌）
夫西地酸是一种有效的抗葡萄球菌药物。
👉针对金黄色葡萄球菌（MSSA和MRSA）：夫西地酸对金黄色葡萄球菌（包括MSSA和MRSA菌株）具有优异的体外活性。在美国以外的许多国家（该药在美国未广泛使用），它被列为治疗金黄色葡萄球菌皮肤软组织感染（如脓疱病和感染性皮肤病）的首选外用药物。在实验性金黄色葡萄球菌创面感染模型中，外用夫西地酸乳膏显示出高度疗效，成功灭活8处创面中的4处感染，而口服头孢氨苄（全身性抗生素）未能清除任何创面中的葡萄球菌。
👉针对化脓性链球菌的活性弱（关键弱点）：这是夫西地酸最重要的临床局限性。数据一致且明确地表明，其对化脓性链球菌的活性充其量是“微不足道的”。
👉证据：体外数据显示对化脓链球菌的最小抑菌浓度（MIC）相对较高，表明其内在活性较差。临床研究也印证了这一结论；一项综述指出，在皮肤感染的对照试验中，除对确诊的链球菌感染病无效外，夫西地酸与对照药物的疗效还是能相当的。
👉直接比较：一项关键实验研究直接比较了莫匹罗星与夫西地酸治疗链球菌感染创面的效果。结果明确显示：治疗链球菌感染时，夫西地酸疗效“显著低于”莫匹罗星。
👉临床意义：这引发重大临床问题。脓疱疮（夫西地酸主要适应症）常为金黄色葡萄球菌与化脓性链球菌的混合感染。单用夫西地酸治疗实属临床赌博：若感染为纯金黄色葡萄球菌，疗效可能良好；但若存在化脓性链球菌，治疗可能失败，导致链球菌感染持续存在，更严重的是，通过消除竞争者而筛选出夫西地酸耐药金黄色葡萄球菌（FRSA）。
（2）夫西地酸耐药性危机
与莫匹罗星类似，夫西地酸的过度使用——尤其作为局部单一疗法——已导致令人震惊的高耐药率。
👉机制：耐药性可由夫西地酸基因（编码EF-G靶点）的染色体突变引起，更令人担忧的是，也可由获得性质粒携带的耐药基因导致。其中最常见的是fusB基因，它能保护细菌核糖体免受抗生素作用。
👉流行状况：在夫西地酸使用地区，夫西地酸耐药性已成为重大临床问题。一项美国研究指出，MSSA和MRSA的低水平耐药率均超过10%，而高水平耐药率≤3.5%。
👉关键2025预印本论文数据：2025年预印本（追踪2016-2023年荷兰数据）揭示了危险且特异的趋势。研究人员发现MRSA菌株中存在统计学意义显著的MRSA耐药性上升趋势。该研究中MRSA分离株的耐药率翻倍增长，从2016年的15%攀升至2023年的30%。此趋势未见于MSSA，表明特定的夫西地酸耐药性MRSA菌株正在社区中扩散。MRSA高达30%的耐药率严重削弱了其作为可靠经验性治疗药物的实用性。
（未完待续，敬请等待下次推文...）
到底是哪些“坏细菌”在皮肤上捣蛋，现有哪种外用抗生素制剂可有效治疗？-（1）
到底是哪些“坏细菌”在皮肤上捣蛋，现有哪种外用抗生素制剂可有效治疗？-（2）
微生物疗法上市批准
2025-12-01
用于抗菌治疗的智能响应材料：进展、机遇与挑战
Progress in Materials Science ( IF 40 )
Pub Date : 2025-07-10 ,
DOI: 10.1016/j.pmatsci.2025.101532
细菌感染威胁着全球人类健康，推动了抗菌材料在过去20年的快速发展。然而，耐药菌的快速存在和生物膜的残酷穿透限制了其临床应用。智能响应式抗菌材料（SRAMs）是一种能够响应内源性/外源性刺激释放抗菌因子的抗菌材料，是开发新一代抗菌材料的重要手段。这些材料可以逃避现有的获得性耐药机制，并且由于其时空可控性和可忽略的副作用，也可以提供一种治疗生物膜的替代策略。SRAM已成为对抗难以治疗的细菌感染的一种有前景的工具。
为了更好地理解SRAM与生物组织之间的相互作用，本文综述了SRAM清除浮游菌和生物膜的机制，以及设计响应内外刺激的SRAM的最新进展。同时，对SRAM的最新研究进展进行了综述。本文概述了内、外刺激响应型智能抗菌材料的特性，并讨论了各种感染性疾病的抗菌应用所需的潜在特性。此外，本文还讨论了目前面临的挑战和未来的发展前景，重点强调了这些智能抗菌平台的临床转化。
01
前 言
1.1. 细菌感染
作为人类，想要改善我们的健康和减少我们的痛苦是我们的天性。生物材料作为生命系统和治疗系统之间的接口，促进组织生物功能的恢复，减轻损伤或疾病状态下的症状。“细菌感染”一词通常用于描述与致病菌生长相关的各种疾病或状况，这些疾病可能导致各种组织出现疾病，包括皮肤、肠道、骨骼、肺、心脏、脑、血液或身体其他任何地方。
细菌感染性疾病对全球公共卫生构成重大威胁[2,3]，可引起各种感染性疾病，如细菌性骨髓炎[4]、细菌性肺炎[5]、植入物表面细菌感染[6]等[7]。据估计，每年约有770万例死亡与细菌感染有关。其中，495万例死亡与耐药病原体相关，而127万例死亡明确归因于对现有抗生素[8]表现出耐药性的细菌病原体。据预测，到2050年，将有1000万人死于由细菌和其他微生物感染引起的疾病[9,10]。《2019年全球疾病、损伤和危险因素负担研究》将大肠埃希菌（大肠埃希菌，革兰阴性菌）和金黄色葡萄球菌（金黄色葡萄球菌，革兰阳性菌）确定为最常见的致病菌[11]。
抗生素仍然是细菌感染临床治疗的基石。亚历山大·弗莱明（Alexander Fleming）在20世纪对青霉素的开创性发现标志着抗菌疗法[13]-[14]的革命性进步。不幸的是，抗生素的过度使用和误用导致抗生素耐药菌[15]的迅速出现。解决这一困境的办法是开发新的抗生素，通常需要10年以上的时间。然而，细菌通常只需要10天就会在实验室条件下产生耐药性。第一个挑战是新抗生素研发时间与耐药菌进化周期的不平衡。
另一个主要挑战是在治疗细菌感染性疾病[17]时清除生物膜内的细菌。生物被膜普遍存在于古细菌和细菌谱系的各种生物中，化石证据可以追溯到大约32.5亿年前。在临床上，生物膜占慢性感染和院内感染的近80%，其包含单种或多种微生物群落[19]。细菌生物膜由密集的细菌细胞群落、非生物表面和胞外多聚物质[20]组成，其结构保护细菌免受抗生素、抗体和免疫细胞的干扰。在生物膜中，耐受性主要是细菌在杀菌抗菌药物存在下的适应性行为，它们会降低非代谢持续性细胞的生长速度或亚群以在[21]中存活。抗性是通过自发突变或水平基因转移[22]发展和传播的。生物被膜中病原菌的耐受性和耐药机制以及生物被膜的结构使清除生物被膜成为[23]面临的另一个挑战。
1.2. 目前的抗菌治疗策略
抗生素是当代医疗保健的基石。在近一个世纪的时间里，它们从细菌感染中拯救了无数的生命。如果不使用抗生素，基本的外科手术和免疫抑制化疗将会造成危及生命的感染风险。然而，耐药机制的不断发展及其在细菌间的传播导致全球缺乏有效的治疗方案[26]。抗生素耐药细菌每年导致约495万人死亡[27,28]。同时，大剂量抗生素会带来许多不良副作用，包括破坏肠道和阴道菌群[29]、神经毒性[30]、肝肾毒性[31]等。开发新抗生素的传统方法主要依赖于对现有药物支架的结构改造。然而，由于多年来对相同化学成分[25]的提炼，这些尝试已无法跟上耐药性的快速蔓延。
生物膜相关感染的治疗是另一个重大挑战。许多传统抗生素由于难以穿透细胞外聚合物基质或过度滞留在生物膜结构内而表现出有限的疗效[32,33]。此外，这些群落中固有抗菌耐受性[34]水平的增加和细菌耐药性的增加进一步损害了治疗结果。免疫原性的缺乏和免疫应答率的不足使得中性粒细胞、巨噬细胞等固有免疫细胞对生物膜[[35]、[36]、[37]]的杀伤能力较差。更令人担忧的是，成熟的细菌生物膜可以破坏抗原呈递途径，从而损害免疫监视机制，阻止微生物的有效清除[38,39]。因此，常规的抗菌化疗不能完全清除生物膜中的细菌，导致耐药菌株的出现和临床持续感染的复发。
研究人员越来越多地转向替代策略来应对这些挑战，这可能更容易取得更好的治疗效果[40,41]。与抗生素相比，基于生物材料的策略具有高度可调性，可以使无效的抗生素有效或在不产生抗生素耐药性的情况下根除病原菌或克服生物膜屏障[17]。自2006年以来，虽然有几种基于生物材料的抗菌疗法进入临床试验，并取得了一定的成功，但没有一种疗法获得了FDA的批准（表1）。近年来，一些新型的方法利用工程生物材料，通过特定的内源性信号（如pH值、氧化还原电位、酶活性等）和外源性信号（如光、超声、微波等）来触发对浮游细菌或生物膜[[42]、[43]、[44]]的抗菌作用，从而实现对抗菌作用的精确时空控制。这些策略不能产生耐药性，也不能使无效的药物发挥作用。
1.3. 智能响应材料
1.3.1. 什么是智能响应材料？
智能材料是指在受到温度、pH等外界或内源性刺激时，其某些特性可被可控或可逆改变的材料。智能材料是细胞生物学、化学和材料科学[45]产生和发展的产物。智能材料也因其响应性而被称为响应材料。它们以前常被翻译为“活性物质”，尽管“活性物质”可能更准确。响应性材料在受到一种或多种刺激时，会改变其一种或多种性质。
20世纪70年代，一项开创性的研究将能够响应内源性/外源性信号并在空间和/或时间上释放信号的材料[[47]，[48]，[49]]应用于生物医学领域。毫无疑问，动态响应系统在自然界中广泛存在，并且经常涉及生命系统的整体过程。例如，细胞可以对周围环境[51]的时间变化做出反应。
1.3.2. 智能响应材料的历史发展
根据智能响应材料的历史发展，可以分为四个阶段。由于对免疫系统的认识有限，第一代材料主要集中在生物惰性材料。1949年，英国眼科医师Ridley在第二次世界大战期间首次发现聚甲基丙烯酸甲酯（PMMA）不会引起眼球炎症，可以作为人工晶状体材料预防白内障[52]。生物材料正慢慢进入人们的视野。20世纪60年代和70年代，第一代生物材料[53]被开发出来，主要目的是获得合适的物理性能，与替代组织匹配，同时在宿主[54]中产生较少的副作用。在这个阶段，生物材料的一个共同特征是它们在生物学上是惰性的，这意味着它们被植入体内时不会引起炎症反应。随着时代的发展，“惰性”的生物材料已经不能满足人们的需求。
将生物活性成分引入生物材料中，得到第二代生物材料[53]。这些材料中的生物活性成分可在生理环境中与内源性刺激发生反应并受控制，形成影响细胞行为的生物活性物质，促进生物材料与组织的整合[55]。然而，第二代生物材料对不断变化的生物环境的适应性较差，导致其在体内的有效性和生存时间较低。
生物体的正常组织可以对变化的生理负荷或生化刺激做出反应，这一概念部分借鉴了第三代生物材料，其特征是能够在分子水平上调节特定的细胞反应[53]。将特定的蛋白质、肽和其他生物分子固定在材料上模拟了细胞外基质环境，为细胞提供了一个多功能的细胞黏附表面[53,56]。这一代生物材料可向细胞提供信号，在一定程度上提高了生物材料在体内的存活率和存活时间。然而，它们在空间和时间上提供信号的能力仍然很小。
这一紧迫的问题催生了第四代生物材料的发展，即智能响应材料（SRMs）的成功开发。如Blumenthal's[47]组利用工程方法构建包裹新霉素的脂质体颗粒，利用局部轻度热使脂质体发生相变，从而调节新霉素的释放率。在有血清存在的情况下，44℃下的新霉素释放率是37℃下的100倍。这种SRMs对细菌感染有较好的治疗效果。布朗利[49]族合成了一种具有生物活性的糖基化胰岛素衍生物，它与刀豆蛋白的主要结合位点结合，因此激素的释放与葡萄糖的量成正比。利用葡萄糖含量控制外源性胰岛素的释放对糖尿病有良好的治疗效果。
1.3.3. 为什么智能响应材料可以用来替代抗生素？
抗生素的发现是20世纪最重要的科学成就之一。当细菌遇到抗生素时，它们变得耐受，然后对[58]产生耐药性。休眠的和未分裂的细菌亚群可以在高浓度的青霉素中存活，导致细菌的持久性[59,60]。减缓或阻止细菌增殖可以促进细菌对抗生素的耐受能力[61,62]。细菌通过基因突变或水平基因转移产生耐药性[63]。抗生素治疗失败通常是由于细菌耐药性[64]。
SRMs如何解决抗生素耐药问题？一般来说，SRMs可以利用各种机制来克服抗生素耐药问题。最初，病原体对抗生素的耐药性主要与特定的靶标结构有关，被称为“锁键原理”[65]。在这种情况下，病原体可以通过特定的突变或外排泵产生对抗生素的耐药性[66]。然而，由于SRMs的非选择性，其作用靶点与抗生素不同，这使得细菌对SRMs产生耐药性具有挑战性。此外，与大多数抗生素不同，药物内化并不是SRMs的先决条件，这进一步有助于克服细菌耐药性[67]。此外，SRMs可以与生物膜的关键成分相互作用，有可能根除生物膜引起的耐药性[68]。此外，SRMs以小剂量局部应用于感染区域，对宿主细胞的伤害最小，并使细菌难以产生耐药性。这些因素使得SRMs成为一种很有前景的消除危及生命的病原体的方法。
治疗学在抗菌治疗中可分为抗生素治疗和非抗生素治疗。前者主要是设计和整合刺激应答载体，以放大抗生素的作用，使无效的药物发挥作用。后者与SRMs产生抗菌底物直接相关，包括活性氧（ROS）、热等。随着时间的推移，通过控制结构和动态功能，形成原理从静态转变为动态，从生物惰性转变为生物复合物，从表面转变为深度。在SRAT过程中，智能材料受到内源性和外源性刺激（包括氧化还原底物、pH、酶、光、温度、US、MW等）的触发，释放抗菌因子，包括ROS、热、金属离子、抗生素、抗菌肽、生物提取物等（图1）。
根据激活时间与线索释放的关系，智能材料可分为三种类型（图1）。第一种是直接激活模式。第一种是它们可以直接对刺激做出反应，释放线索。第二种是序贯模型，基于对每个刺激的成功逐步反应[69]。在进行性激活的系统中，材料暴露于第一类刺激后可以转变为激活模型，然后与第二类刺激反应释放线索。第三种是基于反馈响应模态的自我调节模型。在自我调节平台中，当材料遇到原始刺激时，线索被释放，释放的线索改变了生物组织中的微环境。被调控的微环境会向智能材料反馈，从而调控线索释放的过程。到目前为止，许多研究涉及设计一系列SRAM，可以由内源性刺激（如氧化还原物种，pH值，温度等）和外源性刺激（如光，超声（US），微波（MW）等）触发。这些药物可以进一步释放抗菌因子（如活性氧、热、金属离子、抗生素、抗菌肽、生物提取物等）来治疗细菌感染性疾病，且系统副作用有限。基于SRAM的治疗被命名为智能响应性抗菌治疗（SRAT）。
图1所示。SRAM结合内源性/外源性刺激用于抗菌治疗。pH、温度、氧化还原物种、化学、近红外光、超声和微波是增强抗生素治疗和产生非抗生素抗菌因子的代表性内源性/外源性刺激因素。抗菌因素主要有ROS、热、金属离子、抗生素、抗菌肽、生物提取物等。SRAM触发的抗菌模型主要分为3类。1.直接激活模型包括响应材料，这些响应材料可以在内源性/外源性刺激下释放线索。2.逐步激活模式通常指的是释放线索依赖于两个或两个以上刺激信号的系统。3.自我调节模型最能反映生物组织的内在特性。该系统目前处于初始阶段。工程生物材料是产生合适抗菌物质、调节组织功能以及控制后续抗菌效果的代表性线索。
在之前的几十年里，已经发表了一些与SRAT相关的综述[[70]、[71]、[72]、[73]、[74]、[75]、[76]]。然而，这些文章很少对抗菌/抗生物膜的作用机制、分类、设计原则、响应机制和实际应用进行系统综述。因此，需要及时和全面的审查。本文主要对智能响应型抗菌材料近5年的最新研究进展进行综述。材料的响应机制分为内源性、外源性和复杂响应材料三部分。本文还对其设计原理、优点、抗菌机制以及在治疗细菌感染性疾病中的实际应用进行了讨论（图2）。感染性疾病包括骨感染、肺部感染、骨髓炎、牙周炎、种植体相关感染等。
此外，本文还对设计新一代SRAT及其在体转化潜能面临的挑战和未来的发展方向进行了展望。希望为从事基于智能刺激材料的消毒和材料科学的研究人员提供有价值和全面的信息。
图2所示。SRAT的大纲示意图。将SRAT分为4部分：抗菌机制、可控性质的发展历史、SRMs的设计原则和SRMs在感染性疾病治疗中的应用。
2. 智能响应材料的抗菌机制
SRAM，例如薄膜、纳米粒子或微粒，是对抗细菌感染的替代策略[[77]、[78]、[79]]。了解它们对浮游菌和生物膜的抗菌机制有助于制备更多有用的SRAMs并将其应用于SRAT的各种应用。本节将讨论SRAMs的抗菌机制。
在所有抗菌机制中，杀菌和抑菌作用是最基本的机制。“抑菌剂”是指能够抑制细菌生长，有效地使细菌处于静止状态的药剂；“杀菌剂”是指能够主动杀灭细菌的药剂[80]。在实践中，没有任何一种纯抗微生物药物只属于这一类或那一类。对于抗生素，在试验后18 ~ 24小时内，杀菌剂可清除99.9%以上的细菌。相反，使用抑菌剂可减少90% ~ 99%。临床定义往往更加主观。大多数抗菌药物都有可能同时表现出杀菌和抑菌特性[81]。
SRAMs具有不同于抗生素和传统抗菌材料的特性。带负电荷的AMs通常对革兰阳性菌表现出更好的抗菌能力，而带正电荷的AMs由于结构差异对革兰阴性菌表现出更有效的抗菌作用[82]。图3a为革兰阳性菌和革兰阴性菌的菌膜结构[82]。但是SRAMs没有限制，可以被各种刺激因子（SFs）激活，释放抗菌因子（AF），从而对不同的细菌有很大的抗菌作用（图3a）。
图3所示。SRAMs与细菌相互作用的示意图。(a)针对革兰阳性和革兰阴性细菌的阳性和阴性SRAMs示意图。SF和AF分别是刺激因子和抗菌因子的缩写。(b) SRAMs的抗菌机制说明。SRAMs会产生各种底物，包括热、金属离子、ROS和其他物种，以清除细菌。(c) Cu2O纳米粒子在细菌感染微环境中通过与H2S和H2O2反应来对抗细菌感染的插图[89]。(d) PB在MW辐照下对抗细菌感染的插图。[90] (e)中空结构的Cu2-xS纳米粒子在近红外光照射下对抗细菌的插图[95]。(f)生物膜分散剂联合抗生素复合纳米粒用于卡介苗生物膜感染声动力抗菌化疗示意图。
作为抗生素载体时，SRAMs可以进一步增强抗生素的治疗效果，保护抗生素免受降解酶的影响。SRAMs可以调节抗生素的释放规律，适用于维持感染部位有效的局部药物浓度。这些材料的抗菌机制涉及抗生素和SRAMs的附加元素。SRAMs的引入提高了抗生素的治疗效率，并通过减少所需的全身剂量和脱靶效应进一步减少不良反应。此外，细菌对抗生素的耐药机制包括失活酶、抗生素摄取减少、外排泵、非活性代谢状态、限制抗生素渗透的胞外多聚物质等[83]。基于抗生素的SRAMs可以破坏细胞壁或细胞膜，破坏细胞内成分，从而克服细菌耐药机制。SRAMs利用这些机制使无用的抗生素再次发挥作用。
非抗生素的SRAMs被各种外部刺激激活，产生ROS、热、金属离子等杀菌物质（图3b）。ROS是一种高效的氧化剂，可以作用于细菌的细胞膜和细胞器，最终导致细菌死亡[84]。热量会破坏细菌膜的通透性[85]，进一步改变细菌的代谢，导致细菌死亡。金属离子会改变细菌的代谢，增加细菌内ROS的产生，导致细菌死亡。其他物质如抗菌肽、生物提取物等也会影响细菌的活性。
一般而言，SRAMs主要与细菌膜相互作用，进而影响细胞内物质，最终导致细菌死亡。此外，SRAMs还能有效地清除细菌生物膜。以下部分将详细讨论对浮游菌和生物膜的抗菌机制。
2.1. 浮游细菌
SRAMs对浮游细菌的抗菌机制主要包括破坏细胞壁和细胞膜，破坏细胞内成分，干扰细菌代谢。
图4所示。SRAMs对细菌代谢或生物膜的影响示意图。(a)光激发抗生素多黏菌素b产生ROS来杀死大肠杆菌的示意图[100]。(b)声催化机制和通过基于声动力离子治疗的MN贴片治疗痤疮的示意图。[101](c) Janus Dex-BSe纳米粒子是通过非溶剂介导的反离子络合策略制备的。[108] (d)联合治疗对细菌生物膜影响的示意图，以及US治疗对生物膜的快速破坏和增强抗菌活性的方案。[109] (e)在超声刺激下通过USresponsive catalytic Pip-loaded mb （MB-Pip）消除铜绿假单胞菌生物膜过程的方案。[116]
2.2. 生物膜
生物膜在慢性感染中占80%，在微生物感染中占65%[102]。由于他们的顽固性行为，他们很难治疗和消除[103]。分解细胞外多糖，破坏生物被膜基质，使其内的细菌成为浮游菌，是生物被膜的主要防御机制。与正常组织相比，生物膜感染部位的微环境中H2O2水平升高，pH值降低，细菌产物（如酶、谷胱甘肽等）降低[104]。这些因子可作为刺激激活SRAMs释放抗菌因子。此外，一些外部刺激，包括光、热、微波和磁场，也可以清除细菌。
2.3. SRAMs在外源刺激下杀菌或抑菌活性的动力学
时间-杀灭和浓度-杀灭研究阐明了杀菌或抑菌活性的动力学。SRAMs产生的AF与处理时间和材料浓度有关，提高了抗菌效率。与内源性响应型智能材料相比，外源性响应型智能材料在较短的时间内，尤其是在半小时内表现出良好的抗菌效果。了解抗菌或抑菌作用的动力学对于设计外源性响应性智能材料至关重要。随着刺激时间[43]的延长，细菌数量依次减少。处理时间越长，产生的AF越多，杀菌或抑菌活性越强。
例如，Fe3O4/ CNT/Gent在微波照射5、10、15和20 min后对MRSA的抗菌率分别为6.96%、47.82%、72.68%和99.72%。此外，循环处理可以进一步提高抗菌性能[117]。例如，Ti-RP-SNO + US（1个周期）和Ti-RP-SNO + US（2个周期）的抗菌率分别为93.40%和99.99%[117]。当SRAMs浓度超过一定阈值时，杀伤率也与SRAMs[42]浓度有关。例如，当Bi2S3/Ti3C2Tx-5的浓度为50 ppm或100 ppm时，对金黄色葡萄球菌和大肠杆菌均未观察到有效的细菌清除。当浓度为200 ppm[42]时，近红外照射10 min后，Bi2S3/Ti3C2Tx-5对金黄色葡萄球菌和大肠杆菌的杀灭效率分别达到99.86%和99.92%。
3. 智能响应材料开发过程
自首次出现以来，“智能响应材料”逐渐从简单的静态响应发展到多因素的复杂动态响应，从生物惰性发展到生物复杂性。材料更智能，更好地与生理环境融合。更复杂的物理和生物特性可以被调节和操纵，以更好地适应体内复杂和动态的环境。一是结合生物与材料的内在特性，实现材料的多功能设计；其次，利用生理信号和远程刺激来操纵和控制生物材料的性能，将动态行为引入生物材料中，从而获得复杂的生物学功能。最后，利用光、超声和微波触发的响应材料赋予SRMs治疗深部感染性组织疾病的能力。SAMs的抗菌活性主要与杀菌或抑菌特性有关。
3.1. 从静态到动态
纵观SRMs的发展历史，可以看出SRMs已经从只能对单一应答发展到可以对多个应答。生物材料设计的进步使动态特征融入生物材料平台[118]。它们还可以向周围的细胞和组织提供信号[119]。“活细胞”因能对复杂的代谢物做出反应并自主释放信号而受到越来越多的关注。此外，活细胞在日常生活活动中进化出多种代谢途径，具有很强的生物催化能力。它们可以将水、二氧化碳、无机盐和营养物等原材料转化为一系列生物材料（如多糖、蛋白质、脂质和生物矿物质）。
一些天然材料，如骨、木材或细菌生物膜，可以通过成分、结构和性质的调整来响应环境因素（pH、盐度、温度、光强度或方向、机械应力等）的变化[[120]、[121]、[122]]。自主生长、感知、代谢产物分泌和再生是许多天然生物材料固有的特性[119]。在特定的生活环境中，这类材料会根据环境的特点做出一系列反应，使材料具有动态性能。然而，当单独使用活细胞/活细菌时，对使用环境和储存条件有很大的要求。最有效的方法是利用非生物成分与活细胞或活细菌结合，提高活细胞/活细菌对环境的耐受性，形成“活材料”[123]。
例如，活菌制剂是通过将活枯草芽孢杆菌封装到热响应性水凝胶中形成的[124]。通过改变聚合物浓度与细菌培养基的比例、抑制细菌生长等方法来调节材料的力学特性。如图5所示，活菌制剂没有穿透真皮层，而是穿透角质层，堆积在表皮层，使用后迅速在皮肤表面凝固。凝胶中的枯草芽孢杆菌（B. subtilis）在正常的生命代谢过程中分泌抗真菌物质，有效抑制念珠菌的生长。另外，由于枯草芽孢杆菌被包裹在凝胶中，它不会直接接触到组织，不存在潜在组织细菌感染的问题。该抑菌制剂的抑菌效果与临床上使用的酮康唑相当。
图5所示。活菌剂的形成及其对皮肤感染的治疗。[124]经许可改编。
3.2. 从简单到复杂
SRMs的另一个最新方向是设计响应并集成生物功能的材料系统。这种材料系统超越了生物组织对材料的简单需求，专注于生物组织的表征。从信号处理和交换的角度来看，材料系统被设计成与生物组织更复杂的相互作用。换句话说，智能响应材料系统更注重材料与细胞/细菌之间的相互作用，这是基于对材料/生物界面特性的深入理解。在自然界中，材料和生物元素（如蛋白质、细胞膜、囊泡、细胞器、DNA和生物流体）之间的动态物理化学相互作用、动力学和热力学交换是材料和细胞之间相互作用的例子[125]。
例如Hu课组[126]设计了富集纳米孔的二硫化钼（NR-MoS2），该技术可以根据生物材料界面的特性，通过纳米孔影响材料与细菌之间的电子传递，破坏生物膜细胞外基质的完整性。NR-MoS2和生物膜分别作为电子供体和受体。它们接触后，NR-MoS2中的电子被转移到细菌生物膜中。与细菌生物膜形成相关的基因表达显著下调。生物膜的关键成分也被破坏，包括蛋白质、用于细胞间黏附的多糖、细胞外DNA等[126]。包被细胞膜的纳米粒子可以形成纳米仿生载体粒子[127]。
细胞膜型纳米粒可以模仿特定天然细胞的功能以适应复杂的生理环境，并赋予纳米粒良好的生物相容性和免疫逃逸能力[127]。Zhang等[128]利用表达流感病毒融合蛋白血凝素（HA）的工程细胞细胞膜包裹载mRNA的聚乳酸-羟基乙酸共聚物（PLGA）构建HA-mRNA- np复合纳米载体（HA-mRNA- np复合纳米载体）。细胞膜涂层为纳米载体提供了生物界面，使纳米粒子具有免疫逃逸特性。复合纳米载体被靶细胞内吞后，内吞体内的低pH值导致HA构象发生改变，触发膜融合过程，负载的mRNA逃逸到细胞质中。它被转化为蛋白质产品，治疗随后的疾病。
3.3. 从表面到深处
随着对材料光电特性的深入研究和理解，以及从生理指标角度对材料结构的要求，智能响应材料从短波长（ultraviolet）响应发展到长波长（MW）响应。其中，紫外线和可见光谱中的光在生物组织中的穿透深度只有几毫米[129]。NIR的组织穿透深度为1~2 cm[130,131]。915 MHz和2.45 GHz微波在组织中的穿透深度约为2~4 cm[132]。US的组织穿透深度超过10 cm[133,134]。
从历史的角度来看，基于外源性刺激方法设计相应的外源性智能响应材料，可以实现信号由外向内的可控释放。以这些研究为例[[135]，[136],[137]]。这些纳米平台可以在各种外源刺激（如光、超声和磁）下以可控的方式释放药物[138]。该光响应生物材料系统由抗体前体药物、树突状大分子和上转换纳米粒子组成。紫外光和近红外可作为刺激物调控载药的控释。微泡、泡脂质体、纳米凝胶等超声材料在超声辐照下通过破坏细胞膜，提高细胞内药物递送效率，控制药物释放速率。通过包封、表面涂层或偶联等方式将药物负载于磁性材料上，形成磁响应生物材料系统。在磁场的刺激下，药物在原位释放到目标位置。
文章后半部分请关注公众号
微信公众号丨纳米材料催化
声明：本文版权归原作者所有，转载请联系授权！因学识有限，难免有所疏漏和谬误，肯请批评指正！
推文合作请联系私信联系后台
微生物疗法临床研究
100 项与 硫酸新霉素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部感染 | 中国 | 1984-01-01 | |
| 继发感染 | 日本 | 1964-10-14 | |
| 细菌感染 | 加拿大 | 1953-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床4期 | 37 | (Rabies Vaccine With Antibiotics) | 積鏇範壓觸衊衊簾鹹製(糧積簾鏇蓋繭積窪衊壓) = 鑰醖鏇範衊範淵繭網範 繭製願鬱製願餘餘製構 (壓襯蓋築鬱鏇廠壓願簾, 262.99) 更多 | - | 2023-06-08 | ||
Rabies Vaccine (Rabies Vaccine) | 積鏇範壓觸衊衊簾鹹製(糧積簾鏇蓋繭積窪衊壓) = 膚選醖餘衊願簾壓選顧 繭製願鬱製願餘餘製構 (壓襯蓋築鬱鏇廠壓願簾, 943.85) 更多 | ||||||
临床2期 | 8 | 齋鏇憲淵鹽餘選糧簾衊(願壓鹹積製網蓋鹽壓壓) = 築觸鹹衊餘艱齋襯繭憲 廠範鑰鏇觸構築廠積顧 (淵鏇鬱餘憲壓鑰顧遞簾, 鹽憲壓夢憲鹽壓範淵膚 ~ 鏇齋簾選襯糧網蓋繭鹹) 更多 | - | 2021-02-08 | |||
(Placebo) | 齋鏇憲淵鹽餘選糧簾衊(願壓鹹積製網蓋鹽壓壓) = 築醖醖鹹糧範鹹積範廠 廠範鑰鏇觸構築廠積顧 (淵鏇鬱餘憲壓鑰顧遞簾, 餘糧鹽齋衊壓壓鹹醖餘 ~ 夢襯淵觸顧構廠鏇鏇積) 更多 | ||||||
临床2期 | 12 | (Antibiotics Prior to FMT) | 積淵鏇觸膚繭鬱糧簾鏇(構淵築積餘願鏇膚構遞) = 齋網鹽鑰鏇鏇糧顧範衊 積淵願窪蓋鬱鬱築鏇構 (觸憲網餘鹽選構齋網襯, 0.5) 更多 | - | 2020-11-20 | ||
Fecal Microbiota Transplantation (Placebo Prior to FMT) | 積淵鏇觸膚繭鬱糧簾鏇(構淵築積餘願鏇膚構遞) = 簾鹽選構襯構製衊窪遞 積淵願窪蓋鬱鬱築鏇構 (觸憲網餘鹽選構齋網襯, 0.5) 更多 | ||||||
N/A | 37 | Placebo+Neomycin (Group 1) | 築憲選憲鏇衊繭選夢積(獵選網蓋鏇壓鏇窪構構) = 醖鏇築艱衊壓夢製鹹顧 網蓋糧膚淵鑰築膚壓選 (壓蓋築憲願醖蓋繭鏇簾, 24.1) 更多 | - | 2015-08-10 | ||
築憲選憲鏇衊繭選夢積(獵選網蓋鏇壓鏇窪構構) = 範觸觸鏇鹹襯構夢廠簾 網蓋糧膚淵鑰築膚壓選 (壓蓋築憲願醖蓋繭鏇簾, 30.8) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用